|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||102.14 - 103.59|
|52 Week Range||90.10 - 112.97|
|PE Ratio (TTM)||21.61|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||1.80 (1.77%)|
|1y Target Est||102.07|
Fortune's "World's Most Admired Companies" list is based on surveys of 680 companies from 29 countries, asking executives, directors, and analysts to rate enterprises in their own industry on nine criteria, from investment value and quality of management and products to social responsibility and ability to attract talent. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 888-667-5784 for domestic callers or 402-220-6427 for international callers. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on February 1, 2018 until midnight Eastern Time on February 15, 2018. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
LONDON, UK / ACCESSWIRE / January 04, 2018 / Active-Investors has a free review on Quest Diagnostics Inc. (NYSE: DGX ) following the Company's announcement that it will begin trading ex-dividend on January ...
SECAUCUS, N.J., Jan. 3, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Wednesday, January 10, 2018 at 12:00 p.m. Eastern Time. At 12:30 p.m. Eastern Time, Mr. Rusckowski will be joined by Mark Guinan, Executive Vice President and CFO, in a Q&A session to be moderated by the host analyst.
Clover Health is struggling to make its start-up health insurance model work after years of missteps.
Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.
Transaction broadens access to Quest's diagnostic innovations in the New York-New Jersey metropolitan area SECAUCUS, N.J. , Dec. 12, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading ...
A U.S. trade association representing medical laboratories filed a lawsuit on Monday challenging a new reimbursement system used by the federal government that it said would reduce how much Medicare pays for labs by about $670 million in 2018. The American Clinical Laboratory Association (ACLA) in a lawsuit in federal court in Washington, D.C., said the U.S. Centers for Medicare & Medicaid Services (CMS) ignored Congressional intent by implementing the new system following the passage of a 2014 law.
SECAUCUS, N.J. , Dec. 11, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced its support for a lawsuit filed by the American ...
The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.
Stock Monitor: China Cord Blood Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 05, 2017 / Active-Investors issued a free report on Quest Diagnostics Inc. (NYSE: DGX ), which is readily accessible ...
SECAUCUS, N.J. and CLEVELAND, Dec. 1, 2017 /PRNewswire/ -- Quest Diagnostics (DGX) today announced that it has completed its previously announced acquisition of Cleveland HeartLab. Quest will establish a national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing 25,000 square-foot clinical laboratory facility in Cleveland.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
SECAUCUS, N.J. , Nov. 29, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
Quest Diagnostics CEO Steve Rusckowski on tax reform, the company's partnership with Walmart, ObamaCare and the company's outlook.